当前位置: X-MOL 学术Digit Biomark. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
NODE.Health Meeting Report and Panel Discussion – The FDA’s Changing Regulatory Landscape for Digital Health Technologies and Digital Health Innovation during COVID-19: A Discussion with Eric Topol and Bakul Patel, Moderated by Aenor Sawyer
Digital Biomarkers Pub Date : 2020-12-03 , DOI: 10.1159/000512681
Anna Andoni 1 , Shayann Ramedani 2 , Benjamin I Rosner 3 , Aenor Sawyer 4
Affiliation  

On August 19th, 2020, the Network of Digital Evidence, NODE.Health, a 501(c)3 nonprofit organization dedicated to accelerating the adoption of digital health technology by creating and promoting best practices in evidence and transformation, hosted a webinar about the changing FDA digital health regulatory landscape and the need to balance speed with evidence [1]. The session included guest panelists Dr. Eric Topol, Founder and Director of the Scripps Research Translational Institute, and Bakul Patel, Director of Digital Health at the Center for Devices and Radiological Health at the Food and Drug Administration (FDA). Received: September 23, 2020 Accepted: October 27, 2020 Published online: December 3, 2020

中文翻译:


NODE.Health 会议报告和小组讨论 – FDA 在 COVID-19 期间不断变化的数字健康技术和数字健康创新监管格局:与 Eric Topol 和 Bakul Patel 的讨论,由 Aenor Sawyer 主持



2020 年 8 月 19 日,数字证据网络 NODE.Health(一家 501(c)3 非营利组织,致力于通过创建和推广证据和转型最佳实践来加速数字医疗技术的采用)举办了一场关于不断变化的网络研讨会FDA 数字健康监管格局以及平衡速度与证据的需要 [1]。会议嘉宾包括斯克里普斯研究转化研究所创始人兼主任 Eric Topol 博士以及美国食品和药物管理局 (FDA) 设备和放射健康中心数字健康主任 Bakul Patel。收稿日期:2020年9月23日 接受日期:2020年10月27日 在线发布日期:2020年12月3日
更新日期:2020-12-03
down
wechat
bug